43
Participants
Start Date
January 1, 2018
Primary Completion Date
October 22, 2019
Study Completion Date
January 30, 2020
Apatinib
Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
SHR-1210
Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing
Peking University Shougang Hospital, Beijing
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Peking University People's Hospital
OTHER